Abstract: The invention relates to treatments for organ rejection, in particular to treatments for lung transplant associated bronchiolitis obliterans syndrome by administering a neutrophil elastase inhibitor, such as alvelestat. The invention also relates to treatments for graft versus host disease.
Type:
Application
Filed:
September 17, 2020
Publication date:
November 10, 2022
Applicants:
MEREO BIOPHARMA 4 LIMITED, DUKE UNIVERSITY, NATIONAL CANCER INSTITUTE
Inventors:
Jacqueline PARKIN, Anthony SUNG, Steven Z. PAVLETIC, Annie IM, Noa G. HOLTZMAN, Cody J. PEER
Abstract: Provided herein are methods for delaying or inhibiting T cell maturation or differentiation in vitro for a T cell therapy, comprising contacting one or more T cells from a subject in need of a T cell therapy with an AKT inhibitor and at least one of exogenous Interleukin-7 (IL-7) and exogenous Interleukin-15 (IL-15), wherein the resulting T cells exhibit delayed maturation or differentiation. In some embodiments, the method further comprises administering the one or more T cells to a subject in need of a T cell therapy.
Type:
Application
Filed:
October 20, 2016
Publication date:
May 18, 2017
Applicants:
Kite Pharma, Inc., National Cancer Institute
Inventors:
Arianne Perez, Marianna Sabatino, Steven A. Rosenberg, Nicholas P. Restifo
Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.
Type:
Application
Filed:
May 27, 2016
Publication date:
December 1, 2016
Applicants:
Kite Pharma, Inc., National Cancer Institute
Inventors:
Adrian BOT, Jeffrey S. WIEZOREK, William GO, Rajul JAIN, James N. KOCHENDERFER, Steven A. ROSENBERG
Abstract: Chronic HIV infection is treated by administering to a subject an organic thiophosphate alone or in combination with another anti-HIV or anti-AIDS drug. The organic thiophosphate is preferably WR 151327, a compound with antioxidant and free radical scavenging activities, or a functional derivative or analogue thereof. WR 151327 suppresses induction of HIV expression in chronically infected cells mediated by cytokines such as TNF.alpha. and GM-CSF. Pharmaceutical compositions comprising at least one organic thiophosphate in combination with one or more anti-HIV or anti-AIDS drugs are also disclosed.
Type:
Grant
Filed:
March 26, 1993
Date of Patent:
October 20, 1998
Assignees:
U.S. Bioscience, Inc., National Institutes of Health, The National Cancer Institute